A tablet’s appearance or reported name is weaker evidence of composition than an appropriately targeted chemical analysis.
The narrative review described counterfeit products sold as Xanax containing etizolam and discussed variable content and polysubstance cases. It also summarized analytical findings involving other benzodiazepines and metabolites. The source illustrates disagreement between marketed identity and measured contents.
The review did not test a representative sample of all tablets sold under that name. Historical case reports do not establish current market prevalence, uniform potency or the contents of a seized tablet in another case. Co-exposures complicate toxicity attribution.
For forensic reconstruction, distinguish patient-reported product names, packaging, tablet testing and biological analytes. Do not infer alprazolam simply from a Xanax label or infer etizolam in every counterfeit product. Identify the laboratory’s actual analyte panel and whether a measured substance could reflect another drug’s metabolism.
Source: Publication PMC11263270. The case-review applications above are interpretive analysis.
Related reading: Carbamazepine–Alprazolam Interaction Modeling Included Autoinduction.